ABSTRACT
Since it was declared a pandemic in early 2020, Coronavirus Disease 2019 (Covid-19) has caused high morbidity and mortality in the world. In view of the urgency of the situation, vaccination efforts are needed to break the chain of disease transmission. Various types of vaccines have been successfully developed and obtained approval for emergency use. However, the effectiveness of these vaccines, both in the short and long term, has not been fully known. This study aimed to examine the effectiveness of vaccination through the kinetics of the antibody response to the administration of the SARS-COV-2 vaccine by examining IgG S-RBD levels. This study was an observational analytic study with a prospective cohort approach carried out between January and November 2021 at Dr. Soetomo General Academic Hospital, Surabaya, Indonesia. Fifty health workers who received Sinovac vaccination in as many as 2 doses underwent venous blood taking and measurement of quantitative S-RBD antibody level. Then, quantitative SRBD IgG antibody levels were measured and recorded in each subject. The mean S-RBD IgG antibody was found to have fluctuation. The titer was found to significantly increase on day 14 and dropped significantly in month 3 (p <0.001). There was a significant difference in S-RBD IgG levels 6 months after vaccination between Covid-19 uninfected groups and Covid-19 infected groups (p <0.001). In a conclusion, two doses of the Sinovac vaccine formed antibodies, although humoral immunity obtained tended to decrease in 3rd month after vaccination to healthy individuals. The average level of S-RBD IgG antibody in the sixth month post-vaccination was found to be significantly different between groups without history and groups with a history of with infection COVID-19. [ FROM AUTHOR] Copyright of Folia Medica Indonesiana (2355-8393) is the property of Universitas Airlangga and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)
ABSTRACT
In the global context of the COVID-19 pandemic, the overall benefits of getting any COVID-19 vaccine approved by the World Health Organization for emergency use outweigh the potential risks, even in people with weakened immune systems, including people living with HIV (PLWH). At present, there are no reports of HIV/hepatitis B virus (HBV) co-infected patients receiving a booster dose of the inactivated COVID-19 vaccine. Here, we describe a patient with HIV/HBV co-infection who did not seroconvert to three doses of the inactivated COVID-19 vaccine.
ABSTRACT
Background: COVID-19 pandemic causes severe acute respiratory syndrome and requires rapid action. The development of effective safe vaccines become a global priority for achieving herd immunity. Vaccination is expected to form specific antibodies against the SARS-CoV-2 spike protein which can neutralize the virus, preventing the virus from binding with ACE 2 receptors. Objective: Evaluating and to know if there any differences of kinetics antibody levels from recipient's anti-IgG S-RBD and NAb with complete second dose CoronaVac Vaccine, to determine the antibody response in preventing SARS-CoV-2. Method: A prospective-cohort study using observational analytics was conducted from January-April 2021 at Dr. Soetomo Hospital, Surabaya. A total of 50 subjects are healthcare workers who received two doses of CoronaVac. The IgG S-RBD and NAb levels were measured on Maglumi 800 device (SNIBE, China). Differences in IgG S-RBD and NAb levels before vaccination and after second dose CoronaVac vaccination on 14th day, on 28th day, ware tested using Friedman and Wilcoxon tests. Result: Mean values of IgG S-RBD and NAb have fluctuated. There was a significant difference between IgG S-RBD and NAb levels on day-0 (0.090 vs 18.630; p < 0.001) and day-28 (141.266 vs 116.640; p = 0.037). The median value showed the IgG S-RBD level on day-28 was much better than NAb value (141,266 v 116,640). Conclusion: CoronaVac will form persistent antibodies. Despite antibody development, the acquired humoral immunity decreased at 28 days after full CoronaVac immunization. Kinetics of antibody NAb decreased more rapidly than IgG S-RBD.